Atrial fibrillation and the pharmacological treatment: the role of propafenone

被引:1
|
作者
Sestito, A. [1 ]
Molina, E. [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Dept Cardiol, I-00168 Rome, Italy
[2] Univ Parma, Sch Med, Dept Pharmacol, I-43100 Parma, Italy
关键词
Atrial fibrillation (AF); Acute onset AF; Prevention of AF recurrences; Antiarrhythmic drugs; Propafenone; SINUS RHYTHM; SUSTAINED-RELEASE; ORAL PROPAFENONE; MANAGEMENT; CONVERSION; EFFICACY; PREVENTION; THERAPY; TRIAL; RISK;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Atrial fibrillation is the most frequent cardiac rhythm disturbance, with prevalence increasing with age. This disease is a major risk factor for ischaemic stroke. The costs resulting from atrial fibrillation are really impressive. Pharmacological agents are the first line therapy for the management of atrial fibrillation. Antiarrhythmic drugs are used to terminate arrhythmias, as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. Among antiarrhythmic agents, drugs that inhibit early sodium current (as propafenone) are proven effective in atrial fibrillation. In this review, the most relevant data on propafenone are provided. Discussion: The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses. Propafenone resulted an effective measure as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. In several clinical studies, strong increases of arrhythmia-free periods as well as marked increases in time to recurrence of symptomatic atrial fibrillation, such as paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation were observed. In particular, well-designed clinical studies demonstrated in large patient populations the efficacy of propafenone at several doses. At the suggested doses propafenone is usually well tolerated. Conclusion: The risk of increased occurrence of regular supraventricular arrhythmia or paroxysmal supraventricular tachycardia has been overestimated for propafenone, because this adverse event was seen in all treatment groups, including placebo, with the same (and low) frequency.
引用
收藏
页码:242 / 253
页数:12
相关论文
共 50 条
  • [31] Use of propafenone for conversion of chronic atrial fibrillation in horses
    De Clercq, Dominique
    van Loon, Gunther
    Tavernier, Rene
    Verbesselt, Rene
    Deprez, Piet
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2009, 70 (02) : 223 - 227
  • [32] Preventive effectiveness of propafenone in patients with recurrent atrial fibrillation
    Kurbanov, R. D.
    Zakirov, N. U.
    Azizov, Sh K.
    RUSSIAN JOURNAL OF CARDIOLOGY, 2009, (06): : 40 - 44
  • [33] Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter Comment
    Dabrowska, Barbara
    Kardiologia Polska, 2008, 66 (11) : 1225 - 1225
  • [34] Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery
    Geelen, P
    O'Hara, GE
    Roy, N
    Talajic, M
    Roy, D
    Plante, S
    Turgeon, J
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (03): : 345 - +
  • [35] USEFULNESS OF PROPAFENONE FOR RECURRENT PAROXYSMAL ATRIAL-FIBRILLATION
    CONNOLLY, SJ
    HOFFERT, DL
    AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (12): : 817 - 819
  • [36] Syncope following 'pill-in-the-pocket' treatment of atrial fibrillation with propafenone plus quinidine
    Daniell, Harry W.
    HEART, 2011, 97 (19) : 1626 - 1626
  • [37] Usefulness of ibutitilide in combination with propafenone for the conversion of atrial fibrillation
    Chiladakis, J
    Patsouras, N
    Kalogeropoulos, A
    Kotsaridis, A
    Manolis, AS
    EUROPEAN HEART JOURNAL, 2003, 24 : 280 - 280
  • [38] Comparative Effectiveness of Aksaritmin and Propafenone in the Prevention of Atrial Fibrillation
    Kuchkarov, Husniddin Sh.
    Zakirov, Nodir U.
    Kurbanov, Ravshanbek D.
    INTERNATIONAL JOURNAL OF BIOMEDICINE, 2023, 13 (02) : 224 - 228
  • [39] Comparisons of oral Propafenone and Sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation
    Lee, SH
    Chen, SA
    Tai, CT
    Chiang, CE
    Wen, ZC
    Chen, YJ
    Yu, WC
    Huang, JL
    Fong, AN
    Cheng, JJ
    Chang, MS
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (07): : 905 - 908
  • [40] REDUCED PROGRESSION OF ATRIAL FIBRILLATION IN HYPERTENSIVE PATIENTS WITH LONG-TERM TREATMENT OF PROPAFENONE
    Podzolkov, V.
    Tarzimanova, A.
    Gataulin, R.
    JOURNAL OF HYPERTENSION, 2019, 37 : E182 - E182